$2.13
-0.0050-0.23%
At Close: -
$2.14
0.020.71%
After Hours: 8:34 AM EDT
15 minutes delayed
Comments
Loading...
SCYNEXIS
SCYXNASDAQ
Latest news for SCYNEXIS (NASDAQ:SCYX) Stock
SCYNEXIS Stock (NASDAQ: SCYX)
Categories: All
Wednesday, May 08, 2024
Tuesday, April 30, 2024
Monday, April 01, 2024
Friday, March 29, 2024
Monday, January 29, 2024
Monday, January 08, 2024
Friday, January 05, 2024
Thursday, January 04, 2024
Wednesday, January 03, 2024
Tuesday, January 02, 2024
Monday, November 13, 2023
Tuesday, October 24, 2023
Monday, October 16, 2023
Thursday, September 28, 2023
Monday, September 25, 2023
- Gold Moves Lower; TransCode Therapeutics Shares Surge
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Nasdaq Turns Higher; SCYNEXIS Shares Plunge
- Why Are Antifungal Focused Scynexis Stock Plunging Today?
- U.S. Stocks Open Lower; Chicago Fed Index Falls In August
- SCYNEXIS shares are trading lower after the c...
- SCYNEXIS Is Recalling BREXAFEMME And Temporar...
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- SCYNEXIS Shares Halted, News Pending
Wednesday, August 16, 2023
Tuesday, August 15, 2023
Monday, August 14, 2023
Thursday, July 20, 2023
Wednesday, June 21, 2023
Thursday, May 11, 2023
Thursday, April 13, 2023
Monday, April 03, 2023
Friday, March 31, 2023
Thursday, March 30, 2023
- SCYNEXIS, Maxim Raises Price Target To $10, G...
- Dow Rises 100 Points; Accelerate Diagnostics Shares Spike Higher
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks
- SCYNEXIS shares are trading higher after the ...
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Scynexis Shares To Resume Trade At 7:30 A.M. ...
- GSK and SCYNEXIS Announce Exclusive Agreement To Commercialize And Further Develop Brexafemme To Treat Fungal Infection; SCYNEXIS To Receive $90M Upfront Payment With Future Milestones